Openbookopenbook
Equity
IOVA
+0.0 · +0.00%
USD · NASDAQ

Iovance Biotherapeutics Inc(IOVA) Stock Analysis | Healthcare

USD --+0.00%
Reward59Moderate
Risk37Moderate
75%Data
Thin -89% profit margin · Revenue growing 66% YoY
Profitless Growth
Market Cap:3.76Bn
ⓘ
Reward Rating
59
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
37
Moderate
Risk Assessment
4 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on IOVA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for IOVA, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $9.67.

What is Iovance Biotherapeutics Inc?

, a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.

IOVA · Verdict

Solid reward · moderate risk

IOVA stands out on balance sheet and growth, but watch the cash flow signal.

Based on 88% data coverage

IOVA · Verdict

What’s working & what to watch

Strengths 3

  • Balance sheet89/100

    Current ratio 3.20

  • Growth81/100

    Rev +934.5% CAGR · earnings +0.1%

  • Volatility65/100

    Above average

Watchouts 2

  • Cash flow6/100

    -128% free-cash-flow margin

  • Profitability32/100

    -148% net margin · -40% ROE

Model-based scoring. For information only — not financial advice.

What is Iovance Biotherapeutics Inc?

, a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.76B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (59)

The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

RCUSMid Cap / 3.8B market cap
Arcus Biosciences Inc
Compare
CAMRFMid Cap / 3.8B market cap
Camurus AB (publ)
Compare
CNTAMid Cap / 3.7B market cap
Centessa Pharmaceuticals PLC ADR
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap3.76B
P/E RatioN/A
Dividend YieldN/A
Beta0.701
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.